No annual revenue total was found in Polaryx Therapeutics, Inc.'s SEC filings.
Polaryx Therapeutics, Inc. (PLYX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-8.98M
Operating cash flow
$-3.94M
Free cash flow
—
EPS
$-0.20
Dividend per share
None
Shares outstanding
47.34M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PLYX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Paramus, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2075320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$7.8M |
| Net income | -$9.0M |
| Diluted EPS | -$0.20 |
| Operating cash flow | -$3.9M |
| Total assets | $5.2M |
| Total liabilities | $605,000 |
| Stockholders' equity | $4.6M |
| Cash and investments | $5.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 28, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 21, 2026 | Jul 19, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 16, 2026 |
All 35 Polaryx Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.